治験一覧
8,963 件中 2101〜2120 件を表示
駆出率低下を伴う慢性心不全患者を対象としたLY3461767の研究
The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.
閉塞性睡眠時無呼吸低呼吸患者における TS-142 の臨床薬理試験。
A study to evaluate the respiratory safety of TS-142 in patients with mild obstructive sleep apnea hypopnea.
日本人を対象としたJNJ-75220795の研究
The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.
再発性/持続性卵巣明細胞癌患者におけるCYH33の有効性と安全性を評価する研究
The purpose of this study is to determine the treatment efficacy of CYH33 monotherapy in patients with recurrent or persistent ovarian, fallopian tube or primary peritoneal clear cell carcinoma harboring PIK3CA hotspot mutation, who received prior systemic anti-tumor treatment.
基礎疾患を有する集団における家族関係の特別調査
Post-marketing study, Cohort study of COMIRNATY vaccines. To collect information on adverse events and COVID-19 observed after vaccination with COMIRNATY and to assess safety in patients with underlying disease considered to be at high risk of aggravation of COVID-19 who have received vaccination with this product under actual use conditions.
腹膜透析を受けている高リン血症患者におけるKHK7791の臨床試験
To evaluate the efficacy of KHK7791 by comparing changes in serum phosphorus levels from baseline values between peritoneal dialysis patients with hyperphosphatemia receiving repeated administration of KHK7791 for 8 weeks and those receiving placebo.
進行・再発大腸がん患者を対象としたPARADIGM探索研究（NCT02394834）のデータの追加解析
The main aim of the study is to check gene change in tumor tissues with an additional analysis of the data from PARADIGM Exploratory Study, which is conducted for people with advanced/recurrent colorectal cancer. In the PARADIGM Exploratory Study (NCT02394834), the drug being tested in this study is called Panitumumab and the main aim of this study is to check side effect from the study treatment (mFOLFOX6 + bevacizumab versus mFOLFOX6 + panitumumab therapy) and check if the study treatment improves symptoms of advanced/recurrent colorectal cancer.
他の治療を受けた多発性骨髄腫患者における、エルラナタマブ単独とダラツムマブとの併用による治験薬について知るための研究
この臨床試験の目的は、(1) BCMA-CD3二重特異性抗体であるエルラナタマブが、ダラツムマブ、ポマリドミド、デキサメタゾンを含む併用療法と比較して、多発性骨髄腫患者により高い効果をもたらすかどうかを検討すること、および(2) 抗CD38モノクローナル抗体であるダラツムマブと併用した場合のエルラナタマブの安全性と有効性を検討することです。レナリドミドを含む前治療歴のある多発性骨髄腫患者が本試験に登録されます。 本試験のパート1では、異なる用量のエルラナタマブとダラツムマブの併用における安全性と有効性を評価します。 本試験のパート2に参加する患者は、エルラナタマブ単独、エルラナタマブとダラツムマブの併用、またはダラツムマブ、ポマリドミド、デキサメタゾンのいずれかの投与群に無作為に割り付けられます。パート2では、(1) エルラナタマブ単独とダラツムマブ、ポマリドミド、デキサメタゾンの併用、および(2) エルラナタマブとダラツムマブの併用の安全性と有効性を評価します。 パート3では、エルラナタマブ単独またはダラツムマブとの併用で治療を受けた患者における感染予防対策の強化の効果を評価します。 本試験に参加するすべての患者は、病状の進行、許容できない副作用の発現、または試験への参加中止を選択するまで、試験治療を受けます。
短腸症候群におけるアプラグルチドの長期安全性を評価するためのオープンラベル延長試験。
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
MLL再構成またはNPM1変異の有無にかかわらず再発性/難治性AML/ALLに対するDSP-5336の研究
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia.
虚血性心筋症患者で冠動脈バイパス手術を受ける患者に対するADR-002K
Ischemic cardiomyopathy undergoing coronary artery bypass surgery
胃癌治療歴のある患者におけるツサミタマブ・ラブタンシン（SAR408701）とラムシルマブの併用
Primary Objectives: Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma Secondary Objectives: * To assess safety and tolerability * To assess durability of response (DOR) * To assess progression-free survival (PFS) * To assess the disease control rate (DCR) * To assess the pharmacokinetics (PK) * To assess the immunogenicity
AB122プラットフォーム調査
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
日本人成人におけるMT-2766の安全性・免疫原性試験（COVID-19）
The objective of this study is to evaluate the safety and immunogenicity of MT-2766 in Japanese adults.
左室駆出率40%超の心不全患者におけるAZD4831の有効性と安全性を評価する試験
This is a randomised, double-blind, placebo-controlled, multi-center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fraction \> 40%. The study will consist of 2 separate parts, Part A and Part B, approximately 660 participants will be randomised in Part A, 820 in Part B.
未治療のTP53変異急性骨髄性白血病患者におけるアザシチジンとマグロリマブの併用と、医師の選択によるアザシチジンとベネトクラックスの併用または強化化学療法の併用との比較試験
The goal of this clinical study is to compare the effectiveness of the study drugs, magrolimab in combination with azacitidine, versus venetoclax in combination with azacitidine in participants with previously untreated TP53 mutant acute myeloid leukemia (AML).
早期アルツハイマー病患者におけるセマグルチドの有効性に関する研究（EVOKE）
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance. The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period. A cerebrospinal fluid (CSF) sub-study will be performed as a part of the study. The sub-study will be performed on a selection of sites based on their experience with CSF sampling and willingness to participate in this sub-study. The endpoints related to this sub-study are exploratory only.
パルボシクリブとレトロゾールを併用したHR+/HER2-進行乳がんの日本人患者の全生存率を評価する研究
This is a retrospective, multicenter, observational study in Japan. The primary objective is to evaluate overall survival (OS) in Japanese patients with HR+/HER2- advanced breast cancer who have been treated with palbociclib plus letrozole. This observational study was planned as follow-up study of Japanese phase 2 study of palbociclib (NCT01684215, phase 2 portion of A5481010 study).
パルボシクリブと内分泌療法併用療法または内分泌療法単剤療法を受けたHR+/HER2-進行乳がんの日本人患者における患者報告アウトカム（PRO）および身体活動を評価する研究
The study is a prospective, multicenter, observational study to evaluate PRO and physical activity using smartphone-based application and wearable device in Japanese patients with HR+/HER2- advanced breast cancer (ABC). Patients will be enrolled into either palbociclib plus endocrine therapy group (Group 1) or endocrine monotherapy group (Group 2) based on the discretion of the treating physician under routine clinical practice. Total target number of patients is approximately one-hundred in this study (About 50 patients in each group). Enrolled patients will download a smartphone-based application for electronic PRO (ePRO), be provided access to and trained on the use of the application to complete baseline, weekly, and cycle-based assessments for 6 cycles (24 weeks). In addition, enrolled patients will be provided with wearable device and requested to wear the device at all-times, except of while bathing and sleeping, for 6 cycles (24 weeks).
全身性重症筋無力症患者における、皮下投与されたエフガルチギモドPH20 SCと静脈内投与されたエフガルチギモドの薬力学的非劣性の評価
The purpose of this study is to investigate the Pharmacodynamics (PD), Pharmacokinetics (PK), safety, tolerability, immunogenicity, and clinical efficacy of efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20) as compared to efgartigimod IV infused in patients with generalized myasthenia gravis (gMG). The study duration is approximately 12 weeks. After screening, patients will be randomized to receive either efgartigimod infusions or efgartigimod PH20 subcutaneously (SC)